Standardized Antihypertensive Treatment Protocol

Shanghai Jiao Tong University School of Medicine

Status: Not yet enrolling

Conditions: Hypertension

Treatments: Drug: Usual Care; Drug: Standard Medical Therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT06790927

Standardized Protocol

Details and patient eligibility

About

Study name: A cluster randomized controlled trial on a standardized antihypertensive treatment protocol.

Objective: To evaluate a simple treatment protocol for China in a real clinic setting.

Study design: In this study, newly identified uncontrolled hypertension or monotherapy for patients with substandard blood pressure are sequentially enrolled and monitored for blood pressure in the office and at home. Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group.

Study population: Men and Women aged 18-80 years (n=400) meeting the inclusion/exclusion criteria.

Randomization and treatment: Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group. In the usual treatment group, the doctor prescribes medication for patients, and advise the patient to take the medication on time and follow-up every 3 months. The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks of treatment, aftre one month amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.

Follow up: 6 months. Sample size: a total of 400 patients should be enrolled in the combination. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in November 2024, Patients enrollment will be performed between Feburary 2025 to Feburary 2026.

Full description

Study name: A cluster randomized controlled trial on a standardized antihypertensive treatment protocol.

Objective: To evaluate a simple treatment protocol for China in a real clinic setting.

Study design: In this study, newly identified uncontrolled hypertension or monotherapy for patients with substandard blood pressure are sequentially enrolled and monitored for blood pressure in the office and at home. Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group.

Study population: Men and Women aged 18-80 years (n=400) meeting the inclusion/exclusion criteria. Inclusion Criteria: (1) Age 18-80 years; (2) Newly identified or monotherapy patients with uncontrolled clinical blood pressure; (3) Systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90 mmHg; (4) Agree to participate in the trial and sign the informed consent form. Exclusion criteria: (1) The arm circumference is too large or too small (<17cm or >42cm) ; (2) suspected or definite secondary hypertension; (3) Combined with eGFR < 30 ml/min/1.73m2 or end-stage renal disease; (4) Cardiovascular and cerebrovascular events have occurred in the past 3 months, such as myocardial infarction, stroke, acute heart failure, causes Unstable angina pectoris, hospitalization or revascularization of coronary artery disease or bypass graft surgery; (5) Combined with liver damage: aspartate aminotransferase [AST] or alanine aminotransferase [ALT] or total bilirubin at 2 times or more of the upper limit of normal; (6) Concomitant physical diseases with survival expectations of less than 3 years, or tumors diagnosed in the past 2 years and requiring treatment; (7) The investigator assessed that participation in the study was unfavorable to the subject.

Randomization and treatment: Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group. In the usual treatment group, the doctor prescribes medication for patients, and advise the patient to take the medication on time and follow-up every 3 months. The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks of treatment, aftre one month amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.

Follow up: 6 months. Sample size: At least 200 eligible patients should be enrolled in each group, a total of 400 patients should be enrolled in the combination.

Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in November 2024, Patients enrollment will be performed between Feburary 2025 to Feburary 2026. Database construction and statistical analysis will be conducted at the same time, appropriate domestic and international conferences will be selected to publish the research results. The main results will be published in international professional medical journals.

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-80 years;
2. Newly identified or monotherapy patients with uncontrolled clinical blood pressure;
3. Systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90 mmHg;
4. Agree to participate in the trial and sign the informed consent form.

Exclusion criteria

1. The arm circumference is too large or too small (<17cm or >42cm) ;
2. suspected or definite secondary hypertension;
3. Combined with eGFR < 30 ml/min/1.73m2 or end-stage renal disease;
4. Cardiovascular and cerebrovascular events have occurred in the past 3 months, such as myocardial infarction, stroke, acute heart failure, causes Unstable angina pectoris, hospitalization or revascularization of coronary artery disease or bypass graft surgery;
5. Combined with liver damage: aspartate aminotransferase [AST] or alanine aminotransferase [ALT] or total bilirubin at 2 times or more of the upper limit of normal;
6. Concomitant physical diseases with survival expectations of less than 3 years, or tumors diagnosed in the past 2 years and requiring treatment;
7. The investigator assessed that participation in the study was unfavorable to the subject.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

400 participants in 2 patient groups

usual treatment group

Active Comparator group

Treatment:

Drug: Usual Care

standard treatment group

Experimental group

Treatment:

Drug: Standard Medical Therapy